We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 18.00 | 23.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSUMM Summit Therapeutics plc ('Summit', 'the Company') SUMMIT ANNOUNCES CHANGE OF REGISTERED COMPANY ADDRESS Oxford, UK, 30 March 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that the registered office address of the Company has changed to 136a Eastern Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4SB, UK with immediate effect. All other details remain the same including the Company's website (www.summitplc.com), telephone number (+44 (0) 1235 443 939) and fax number (+44 (0) 1235 443 999). This announcement has been made in accordance with Rule 17 of the AIM Rules for Companies. About Summit Therapeutics Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc). For more information, please contact: Summit Glyn Edwards / Richard Pye (UK office) Tel: +44 (0)1235 443 951 Erik Ostrowski / Michelle Avery (US office) +1 617 225 4455 Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880 Liam Murray / Tony Rawlinson -END- This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Summit Therapeutics plc via Globenewswire http://www.summitplc.com/
(END) Dow Jones Newswires
March 30, 2017 09:00 ET (13:00 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Summit Therapeutics Chart |
1 Month Summit Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions